Treatment options and patient perspectives in the management of fibromyalgia: future trends

Kim LawsonBiomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UKAbstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Kim Lawson
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/1ebe2bb6c362452188fdf89c5b8268a5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1ebe2bb6c362452188fdf89c5b8268a5
record_format dspace
spelling oai:doaj.org-article:1ebe2bb6c362452188fdf89c5b8268a52021-12-02T00:56:50ZTreatment options and patient perspectives in the management of fibromyalgia: future trends1176-63281178-2021https://doaj.org/article/1ebe2bb6c362452188fdf89c5b8268a52008-11-01T00:00:00Zhttp://www.dovepress.com/treatment-options-and-patient-perspectives-in-the-management-of-fibrom-a2577https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Kim LawsonBiomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UKAbstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological (education and exercise) interventions. It is a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Recently, drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identified that demonstrate a multidimensional efficacy in this condition. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies.Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological treatments Kim LawsonDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 6, Pp 1059-1071 (2008)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Kim Lawson
Treatment options and patient perspectives in the management of fibromyalgia: future trends
description Kim LawsonBiomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UKAbstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological (education and exercise) interventions. It is a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Recently, drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identified that demonstrate a multidimensional efficacy in this condition. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies.Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological treatments
format article
author Kim Lawson
author_facet Kim Lawson
author_sort Kim Lawson
title Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_short Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_full Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_fullStr Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_full_unstemmed Treatment options and patient perspectives in the management of fibromyalgia: future trends
title_sort treatment options and patient perspectives in the management of fibromyalgia: future trends
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/1ebe2bb6c362452188fdf89c5b8268a5
work_keys_str_mv AT kimlawson treatmentoptionsandpatientperspectivesinthemanagementoffibromyalgiafuturetrends
_version_ 1718403369436971008